Showing results (121-130 of 143) with videos related to
Sort By:
Pageof 15
The New England Journal of Medicine|October 2, 2012
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsKeith T Flaherty, Jeffery R Infante, Adil Daud, et al.Melanoma Research|May 12, 2009
A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrenceKevin B Kim, Sewa S Legha, Rene Gonzalez, et al.The Lancet. Oncology|July 19, 2012
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialGerald S Falchook, Karl D Lewis, Jeffrey R Infante, et al.The New England Journal of Medicine|June 3, 2011
gp100 peptide vaccine and interleukin-2 in patients with advanced melanomaDouglas J Schwartzentruber, David H Lawson, Jon M Richards, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With TrametinibGeorgina V Long, Jeffrey S Weber, Jeffrey R Infante, et al.The New England Journal of Medicine|February 24, 2012
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenibJeffrey A Sosman, Kevin B Kim, Lynn Schuchter, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2013
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skinF Stephen Hodi, Christopher L Corless, Anita Giobbie-Hurder, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2014
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitorDouglas B Johnson, Keith T Flaherty, Jeffrey S Weber, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 2021
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced MelanomaJedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.Nature Reviews. Clinical Oncology|August 29, 2013
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanomaHoward L Kaufman, John M Kirkwood, F Stephen Hodi, et al.Pageof 15